Posts Tagged: healthcare

MaRS Innovation announces new strategic partnership with Pfizer

TORONTO, April 22, 2013 — MaRS Innovation, a Centre of Excellence for Commercialization and Research, today announced the formation of a strategic partnership with Pfizer Inc. to advance early-stage technologies related to human health in therapeutics and diagnostics. Through this collaboration, MaRS Innovation and Pfizer will jointly identify investment opportunities emerging from well-validated scientific research discoveries within MaRS Innovation’s 16 member institutions, including the University of Toronto and its nine affiliated teaching hospitals. “There’s growing consensus that transferring technologies from the university lab ... Read more

Merck invests in pan-Canadian life sciences research innovation sector

A $4-million public-private partnership will promote research innovation involving three academic commercialization centres in Canada CHICAGO, Illinois – April 22, 2013 – Merck Canada will be announcing today at the BIO International Convention that it is reinforcing its commitment to the Canadian life sciences research innovation sector. Merck will provide $4 million in funding to the Institute for Research in Immunology and Cancer – Commercialization of Research (IRICoR) for future corridor projects developed in collaboration with two other Canadian Centres of Excellence for ... Read more

Xconomy names Xagenic to 2012’s Biotech Startup Class

MI spin-off company one of 30 listed in North America and the United Kingdom Xconomy, a U.S.-based business news website, named Xagenic to its 2012 Biotech Startup Class. Luke Timmerman's article, published December 3, 2012, sited Xagenic as one of only 30 "exciting biotech startups" to raise significant venture capital (at least $5 million) in the life sciences sector. Xagenic, founded by Drs. Shana Kelley and Ted Sargent at the University of Toronto,  was also the only Canadian company named to the list. (more…) Read more

Shotlst: “Track changes” for the physical world

Shotlst is one of six inaugural UTEST companies; next UTEST application round to begin shortly What if you could turn on Microsoft Word’s “track changes” tool and apply it at will to the world around you? Sound like science fiction? Meet Matt Ratto, a professor in the University of T’s Faculty of Information, and Mike Borg, a recent graduate of the faculty. They’ve formed Shotlst, a new software company being incubated by the University of Toronto Early Stage Technology (UTEST) program. The central metaphor of ... Read more

Raphael Hofstein’s editorial in National Post’s Medical Devices supplement

MaRS Innovation's President and CEO, Raphael Hofstein, has published an editorial outlining the challenges facing entrepreneurs seeking to bring new healthcare innovations to market for the National Post's Medical Devices supplement. The article, titled "Investing in innovation for a healthier Canada," is available on page 2 of the Post supplement. Posted by Elizabeth Monier-Williams, marketing and communications officer. Read more

Xagenic secures $1 million investment from Ministry of Research & Innovation

Provincial Investment Supports Commercialization of Leading-Edge Molecular Diagnostic Screening Technology TORONTO (July 26, 2011) — Xagenic Inc., one of MaRS Innovation’s (MI) portfolio spin-off companies, was awarded $1 million in funding by Ontario’s Ministry of Research and Innovation (MRI) through its Investment Accelerator Fund‐Life Sciences (IAF-­LS) program. Research and Innovation Minister Glen Murray made the announcement at MaRS Discovery District. “Today’s announcement will go a long way in helping us to commercialize a technology that will ultimately shape the future of diagnostic testing — instead ... Read more

MaRS Innovation and GlaxoSmithKline Announce Strategic Partnership to Accelerate Translational Research in Health Sciences

TORONTO (May 31, 2011) — MaRS Innovation (MI) and GlaxoSmithKline Inc. (GSK) today announced a new development fund — the GSK-MaRS Innovation Fund — that will support and fast-track the commercialization of some of the country’s most promising translational research coming from 16 leading academic health sciences centres, hospitals and universities derived from MI’s member institutions. “From the discovery of insulin in 1922 to the discovery of stem cells, Ontario has a rich, proud history of world-class medical and scientific breakthroughs,” said ... Read more

Vasculotide: sanofi-aventis, Sunnybrook and MI – Article in the Globe and Mail

A discovery that could help millions of diabetics worldwide is the subject of a lucrative pharmaceutical deal that will enrich the Toronto hospital that created it - part of a growing trend of selling science to help shore up Canada's troubled health-care system. Tuesday's agreement between Sanofi-Aventis and Sunnybrook Health Sciences Centre on a wound-healing molecule demonstrates how entrepreneurial hospitals can become when the very sustainability of medicare is in question. But the licensing deal with one of the world's biggest drug companies ... Read more

Wound Healing Technology Exclusive Rights Deal with Cardium Therapeutics

TORONTO
 (October
 14,
 2010)
 –
 Of
 the
 approximately
 300
 million
 people
 around
 the
 world
 who
 are
 diabetics,
 45
 million
 of
 them
 develop 
foot
 ulcers 
that 
bleed
 – 
and 
the 
infection
 from
 those 
ulcers
 can 
spread. Working
 to
 halt
 this
 is
 Dr.
 Ping
 Lee,
 a
 professor
 at
 the
 University
 of
 Toronto’s (U of T)
 Leslie
 Dan
 Faculty
 of
 Pharmacy
 and
 GlaxoSmithKline
 chair
 in
 Pharmaceutics
 and 
Drug 
Delivery.
 He 
and 
his
 team
 have 
created 
a 
new 
sustained‐release
 form
 of
 nitric 
oxide 
(NO) 
that
 can
 not
 ... Read more

MaRS Innovation and Sunnybrook Health Sciences Centre Partner to Develop Four Exciting Medical Discoveries

TORONTO (March 23, 2010) — MaRS Innovation and Sunnybrook Health Sciences Centre have entered into their first set of agreements to collaboratively commercialize a novel therapeutic technology and three advances in medical imaging. These four technologies will impact diagnosis and care for epidemic chronic illnesses and have clear and broad commercial potential. MI will shepherd these opportunities through the next stages of the commercialization process. “We are coming out of the gate vigorously in identifying this group of Sunnybrook technologies as commercialization ... Read more
Page 3 of 41234